Dermata Therapeutics, Inc.
NASDAQ: DRMAW0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Gerald T. Proehl
- Employees
- 8
- Headquarters
- San Diego, United States
- IPO year
- 2021
- Market cap
- $8.6K
- Website
- http://www.dermatarx.com
Loading DRMAW…
Loading profile data…Frequently asked questions about DRMAW
What does Dermata Therapeutics, Inc. (DRMAW) do?
Dermata Therapeutics, Inc., a biotechnology company in the clinical development stage, is headquartered in San Diego, California, and was established in 2014. The firm's core mission is to develop innovative treatments for a variety of dermatological and cosmetic skin conditions. Its flagship investigational product, DMT310, is a topical formula...
Where does DRMAW trade?
Dermata Therapeutics, Inc. (DRMAW) trades on the NASDAQ Capital Market.
What sector is DRMAW in?
Dermata Therapeutics, Inc. (DRMAW) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Dermata Therapeutics, Inc.?
Gerald T. Proehl is the chief executive officer of Dermata Therapeutics, Inc. (DRMAW).
Where is Dermata Therapeutics, Inc. headquartered?
Dermata Therapeutics, Inc. is headquartered in United States.
Does DRMAW pay a dividend?
Dermata Therapeutics, Inc. (DRMAW) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did DRMAW go public?
Dermata Therapeutics, Inc. (DRMAW) completed its initial public offering in 2021.